Second assessment of OVERCOME data
The second assessment employed the migraine Treatment Optimization Questionnaire (mTOQ), which measures the adequacy of acute therapy. The study population was divided into three groups:
• Persons not currently on an oral triptan but with a history of use and discontinuation of at least 2 of them
• Persons currently using an oral triptan with mTOQ sum score <6 (poor/very poor treatment efficacy) and history of failing at least one oral triptan
• Persons with potential contraindications to triptans (eg, cardiovascular conditions or procedures)
Overall, the researchers found that, irrespective of group designation, 27% of persons with three or fewer MHD per month and 33% of those with four or more appeared to be eligible for novel medications designed for acute treatment of migraine. A quarter of the eligible population with three or fewer monthly MHD were currently using an oral triptan despite it being either contraindicated or providing poor/very poor effectiveness. The same percentage reported using opioids.
A third of persons with four or more monthly MHD were using oral triptans and about 30% were using opioids. Barbiturates were used by 13% of those with three or fewer and 16% of those with four or more MHD.
1. Lipton RB, Araujo AB, Nicholson RA, et al. Patterns of diagnosis, consultation, and treatment of migraine in the US: results of the OVERCOME Study. (2017-229-001).
2. Lipton RB, Pohl GM, Araujo AB, et al. Who is eligible for novel medications designed for the acute treatment of migraine and what are their unmet needs? Results of the OVERCOME Study. (2017-6229-004).
3. American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59:1-18.